For: | Nakagawa H. Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis. World J Hepatol 2015; 7(17): 2110-2118 [PMID: 26301053 DOI: 10.4254/wjh.v7.i17.2110] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v7/i17/2110.htm |
Number | Citing Articles |
1 |
Jonathan M. Ploeger, Juan C. Manivel, Lauren N. Boatner, Douglas G. Mashek. Caloric Restriction Prevents Carcinogen-Initiated Liver Tumorigenesis in Mice. Cancer Prevention Research 2017; 10(11): 660 doi: 10.1158/1940-6207.CAPR-17-0174
|
2 |
Veronica Jimenez, Claudia Jambrina, Estefania Casana, Victor Sacristan, Sergio Muñoz, Sara Darriba, Jordi Rodó, Cristina Mallol, Miquel Garcia, Xavier León, Sara Marcó, Albert Ribera, Ivet Elias, Alba Casellas, Ignasi Grass, Gemma Elias, Tura Ferré, Sandra Motas, Sylvie Franckhauser, Francisca Mulero, Marc Navarro, Virginia Haurigot, Jesus Ruberte, Fatima Bosch. FGF21 gene therapy as treatment for obesity and insulin resistance. EMBO Molecular Medicine 2018; 10(8) doi: 10.15252/emmm.201708791
|
3 |
Fang Wang, Ye Zhang, Jianliang Shen, Bin Yang, Weiwei Dai, Junrong Yan, Sara Maimouni, Heineken Q. Daguplo, Sara Coppola, Yingtang Gao, Yijun Wang, Zhi Du, Kesong Peng, Hui Liu, Qin Zhang, Fei Tang, Peng Wang, Shenglan Gao, Yongbo Wang, Wen-Xing Ding, Grace Guo, Fengmei Wang, Wei-Xing Zong. The Ubiquitin E3 Ligase TRIM21 Promotes Hepatocarcinogenesis by Suppressing the p62-Keap1-Nrf2 Antioxidant Pathway. Cellular and Molecular Gastroenterology and Hepatology 2021; 11(5): 1369 doi: 10.1016/j.jcmgh.2021.01.007
|
4 |
Chad VanSant-Webb, Hayden K. Low, Junko Kuramoto, Claire E. Stanley, Hantao Qiang, Audrey Y. Su, Alexis N. Ross, Chad G. Cooper, James E. Cox, Scott A. Summers, Kimberley J. Evason, Gregory S. Ducker. Phospholipid isotope tracing suggests β-catenin-driven suppression of phosphatidylcholine metabolism in hepatocellular carcinoma. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2024; 1869(6): 159514 doi: 10.1016/j.bbalip.2024.159514
|
5 |
Marie Liebig, Dirk Dannenberger, Brigitte Vollmar, Kerstin Abshagen. n-3 PUFAs reduce tumor load and improve survival in a NASH-tumor mouse model. Therapeutic Advances in Chronic Disease 2019; 10 doi: 10.1177/2040622319872118
|
6 |
Yusuke Ozawa, Takafumi Tamura, Yohei Owada, Yoshio Shimizu, Akira Kemmochi, Katsuji Hisakura, Takashi Matsuzaka, Hitoshi Shimano, Hiroko Isoda, Nobuhiro Ohkohchi. Evaluation of safety for hepatectomy in a novel mouse model with nonalcoholic-steatohepatitis. World Journal of Gastroenterology 2018; 24(15): 1622-1631 doi: 10.3748/wjg.v24.i15.1622
|
7 |
Shigeyuki Kurosaki, Hayato Nakagawa, Yuki Hayata, Satoshi Kawamura, Yuki Matsushita, Tomoharu Yamada, Koji Uchino, Yoku Hayakawa, Nobumi Suzuki, Masahiro Hata, Mayo Tsuboi, Hiroto Kinoshita, Yasuo Tanaka, Takuma Nakatsuka, Yoshihiro Hirata, Keisuke Tateishi, Kazuhiko Koike. Cell fate analysis of zone 3 hepatocytes in liver injury and tumorigenesis. JHEP Reports 2021; 3(4): 100315 doi: 10.1016/j.jhepr.2021.100315
|
8 |
Michelle Dow, Rachel M. Pyke, Brian Y. Tsui, Ludmil B. Alexandrov, Hayato Nakagawa, Koji Taniguchi, Ekihiro Seki, Olivier Harismendy, Shabnam Shalapour, Michael Karin, Hannah Carter, Joan Font-Burgada. Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proceedings of the National Academy of Sciences 2018; 115(42) doi: 10.1073/pnas.1811029115
|
9 |
Xu Shi, Wenyan Jiang, Xiaoguang Yang, Yanan Li, Xiaodan Zhong, Junqi Niu, Ying Shi. TIR8 protects against nonalcoholic steatohepatitis by antagonizing lipotoxicity-induced PPARα downregulation and reducing the sensitivity of hepatocytes to LPS. Translational Research 2024; 272: 68 doi: 10.1016/j.trsl.2024.06.002
|
10 |
|
11 |
Paweł A. Kołodziejski, Ewa Pruszyńska-Oszmałek, Mathias Z. Strowski, Krzysztof W. Nowak. Long-term obestatin treatment of mice type 2 diabetes increases insulin sensitivity and improves liver function. Endocrine 2017; 56(3): 538 doi: 10.1007/s12020-017-1309-2
|
12 |
Stephen L. Chan, Alissa M. Wong, Kirsty Lee, Nathalie Wong, Allen K.C. Chan. Personalized therapy for hepatocellular carcinoma: Where are we now?. Cancer Treatment Reviews 2016; 45: 77 doi: 10.1016/j.ctrv.2016.02.008
|
13 |
Lichen Bao, Jun Yin, Wen Gao, Qun Wang, Wenbing Yao, Xiangdong Gao. A long‐acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non‐alcoholic steatohepatitis partly through an FGF21‐adiponectin‐IL17A pathway. British Journal of Pharmacology 2018; 175(16): 3379 doi: 10.1111/bph.14383
|
14 |
Charles I. V. Drummer, Fatma Saaoud, Yu Sun, Diana Atar, Keman Xu, Yifan Lu, Ying Shao, Candice Johnson, Lu Liu, Huimin Shen, Nirag C. Jhala, Xiaohua Jiang, Hong Wang, Xiaofeng Yang, Baohui Xu. Hyperlipidemia May Synergize with Hypomethylation in Establishing Trained Immunity and Promoting Inflammation in NASH and NAFLD. Journal of Immunology Research 2021; 2021: 1 doi: 10.1155/2021/3928323
|
15 |
Turan Aghayev, Aleksandra M. Mazitova, Jennifer R. Fang, Iuliia O. Peshkova, Matthew Rausch, Manhsin Hung, Kerry F. White, Ricard Masia, Elizaveta K. Titerina, Aliia R. Fatkhullina, Isabelle Cousineau, Simon Turcotte, Dmitry Zhigarev, Anastasiia Marchenko, Svetlana Khoziainova, Petr Makhov, Yin Fei Tan, Andrew V. Kossenkov, David L. Wiest, John Stagg, Xin Wei Wang, Kerry S. Campbell, Amiran K. Dzutsev, Giorgio Trinchieri, Jonathan A. Hill, Sergei I. Grivennikov, Ekaterina K. Koltsova. IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma. Cancer Discovery 2022; 12(8): 1960 doi: 10.1158/2159-8290.CD-20-1628
|
16 |
Haider Ghazanfar, Sameer D Kandhi, Iqra Nawaz, Nismat Javed, Minu C Abraham, Mohamed Farag, Jaydeep Mahasamudram, Vishwa B Patel, Faryal Altaf, Harish Patel. Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article. Cureus 2021; doi: 10.7759/cureus.15141
|
17 |
Damien Chua, Zun Siong Low, Guo Xiang Cheam, Aik Seng Ng, Nguan Soon Tan. Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm. International Journal of Molecular Sciences 2022; 23(23): 14762 doi: 10.3390/ijms232314762
|
18 |
Wen Dai, Mark Castleberry, Ze Zheng. Tale of two systems: the intertwining duality of fibrinolysis and lipoprotein metabolism. Journal of Thrombosis and Haemostasis 2023; 21(10): 2679 doi: 10.1016/j.jtha.2023.08.004
|
19 |
Zhi Li, Wen-Qi Gao, Peng Wang, Tian-Qi Wang, Wen-Chao Xu, Xin-Yu Zhu, Hui Liu. Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN-γ Signaling. Current Cancer Drug Targets 2020; 20(11): 868 doi: 10.2174/1568009620999200730184514
|
20 |
James M. Henderson, Natasa Polak, Jinbiao Chen, Ben Roediger, Wolfgang Weninger, James G. Kench, Geoffrey W. McCaughan, Hui Emma Zhang, Mark D. Gorrell. Multiple liver insults synergize to accelerate experimental hepatocellular carcinoma. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-28486-8
|
21 |
Hayato Nakagawa, Yuki Hayata, Satoshi Kawamura, Tomoharu Yamada, Naoto Fujiwara, Kazuhiko Koike. Lipid Metabolic Reprogramming in Hepatocellular Carcinoma. Cancers 2018; 10(11): 447 doi: 10.3390/cancers10110447
|
22 |
Moris Sangineto, Rosanna Villani, Francesco Cavallone, Antonino Romano, Domenico Loizzi, Gaetano Serviddio. Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma. Cancers 2020; 12(6): 1419 doi: 10.3390/cancers12061419
|
23 |
Xue Li, Yajun Lian, Weiwei Ping, Kunbo Wang, Lingyan Jiang, Shaoxia Li. Abdominal obesity and digestive system cancer: a systematic review and meta-analysis of prospective studies. BMC Public Health 2023; 23(1) doi: 10.1186/s12889-023-17275-2
|
24 |
Kenichiro Enooku, Hayato Nakagawa, Naoto Fujiwara, Mayuko Kondo, Tatsuya Minami, Yujin Hoshida, Junji Shibahara, Ryosuke Tateishi, Kazuhiko Koike. Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma. Scientific Reports 2019; 9(1) doi: 10.1038/s41598-019-47216-2
|
25 |
May G. Akl, Scott B. Widenmaier. Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma. Frontiers in Cell and Developmental Biology 2023; 10 doi: 10.3389/fcell.2022.1089124
|
26 |
Satdarshan P. Monga. Inside-Out or Outside-In: Choosing the Right Model of Hepatocellular Cancer. Gene Expression 2020; 20(2): 139 doi: 10.3727/105221620X15913805462476
|
27 |
Ans Jacobs, Anne‐Sophie Warda, Jef Verbeek, David Cassiman, Pieter Spincemaille. An Overview of Mouse Models of Nonalcoholic Steatohepatitis: From Past to Present. Current Protocols in Mouse Biology 2016; 6(2): 185 doi: 10.1002/cpmo.3
|
28 |
Letizia Satriano, Monika Lewinska, Pedro M. Rodrigues, Jesus M. Banales, Jesper B. Andersen. Metabolic rearrangements in primary liver cancers: cause and consequences. Nature Reviews Gastroenterology & Hepatology 2019; 16(12): 748 doi: 10.1038/s41575-019-0217-8
|
29 |
Nathan A. Berger. Young Adult Cancer: Influence of the Obesity Pandemic. Obesity 2018; 26(4): 641 doi: 10.1002/oby.22137
|
30 |
Takahiro Kodama, Jing Yi, Justin Y. Newberg, Jean C. Tien, Hao Wu, Milton J. Finegold, Michiko Kodama, Zhubo Wei, Takeshi Tamura, Tetsuo Takehara, Randy L. Johnson, Nancy A. Jenkins, Neal G. Copeland. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis. Proceedings of the National Academy of Sciences 2018; 115(44) doi: 10.1073/pnas.1808968115
|
31 |
Guangyan Wei, Ping An, Kahini A. Vaid, Imad Nasser, Pinzhu Huang, Li Tan, Shuangshuang Zhao, Detlef Schuppan, Yury V. Popov. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer. American Journal of Physiology-Gastrointestinal and Liver Physiology 2020; 318(1): G174 doi: 10.1152/ajpgi.00041.2019
|
32 |
Maria Papanastasatou, Mihalis Verykokakis. Innate-like T lymphocytes in chronic liver disease. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1114605
|
33 |
Marie Liebig, Alireza Hassanzada, Malte Kämmerling, Berit Genz, Brigitte Vollmar, Kerstin Abshagen. Microcirculatory disturbances and cellular changes during progression of hepatic steatosis to liver tumors. Experimental Biology and Medicine 2018; 243(1): 1 doi: 10.1177/1535370217738730
|
34 |
Yohei Owada, Takafumi Tamura, Tomohito Tanoi, Yusuke Ozawa, Yoshio Shimizu, Katsuji Hisakura, Takashi Matsuzaka, Hitoshi Shimano, Noriyuki Nakano, Shingo Sakashita, Toshiya Matsukawa, Hiroko Isoda, Nobuhiro Ohkohchi. Novel non‐alcoholic steatohepatitis model with histopathological and insulin‐resistant features. Pathology International 2018; 68(1): 12 doi: 10.1111/pin.12612
|
35 |
Satoshi Kawamura, Yuki Matsushita, Shigeyuki Kurosaki, Mizuki Tange, Naoto Fujiwara, Yuki Hayata, Yoku Hayakawa, Nobumi Suzuki, Masahiro Hata, Mayo Tsuboi, Takahiro Kishikawa, Hiroto Kinoshita, Takuma Nakatsuka, Masaya Sato, Yotaro Kudo, Yujin Hoshida, Atsushi Umemura, Akiko Eguchi, Tsuneo Ikenoue, Yoshihiro Hirata, Motonari Uesugi, Ryosuke Tateishi, Keisuke Tateishi, Mitsuhiro Fujishiro, Kazuhiko Koike, Hayato Nakagawa. Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis. Journal of Clinical Investigation 2022; 132(11) doi: 10.1172/JCI151895
|
36 |
Run Li, Yaqi Lan, Chengyu Chen, Yong Cao, Qingrong Huang, Chi-Tang Ho, Muwen Lu. Anti-obesity effects of capsaicin and the underlying mechanisms: a review. Food & Function 2020; 11(9): 7356 doi: 10.1039/D0FO01467B
|
37 |
Smriti Shreya, Christophe F. Grosset, Buddhi Prakash Jain. Unfolded Protein Response Signaling in Liver Disorders: A 2023 Updated Review. International Journal of Molecular Sciences 2023; 24(18): 14066 doi: 10.3390/ijms241814066
|
38 |
Pavla Staňková, Otto Kučera, Eva Peterová, Halka Lotková, Tumisang Edward Maseko, Kateřina Nožičková, Zuzana Červinková. Adaptation of Mitochondrial Substrate Flux in a Mouse Model of Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences 2020; 21(3): 1101 doi: 10.3390/ijms21031101
|
39 |
Indu G. Rajapaksha, Lakmie S. Gunarathne, Khashayar Asadi, Ross Laybutt, Sof Andrikopoulous, Ian E. Alexander, Mathew J. Watt, Peter W. Angus, Chandana B. Herath. Angiotensin Converting Enzyme‐2 Therapy Improves Liver Fibrosis and Glycemic Control in Diabetic Mice With Fatty Liver. Hepatology Communications 2022; 6(5): 1056 doi: 10.1002/hep4.1884
|
40 |
Naoto Fujiwara, Hayato Nakagawa, Kenichiro Enooku, Yotaro Kudo, Yuki Hayata, Takuma Nakatsuka, Yasuo Tanaka, Ryosuke Tateishi, Yohko Hikiba, Kento Misumi, Mariko Tanaka, Akimasa Hayashi, Junji Shibahara, Masashi Fukayama, Junichi Arita, Kiyoshi Hasegawa, Hadassa Hirschfield, Yujin Hoshida, Yoshihiro Hirata, Motoyuki Otsuka, Keisuke Tateishi, Kazuhiko Koike. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut 2018; 67(8): 1493 doi: 10.1136/gutjnl-2017-315193
|
41 |
C. Nelson Hayes, Peiyi Zhang, Kazuaki Chayama. Hepatocellular Carcinoma. 2019; : 95 doi: 10.15586/hepatocellularcarcinoma.2019.ch5
|
42 |
Hiroyuki Akai, Shigeru Kiryu, Yasunori Ohta, Koichiro Yasaka, Yoshiyasu Nakano, Yusuke Inoue, Kuni Ohtomo. The natural history of streptozotocin-stimulated non-alcoholic steatohepatitis mice followed by Gd-EOB-DTPA-enhanced MRI: Comparison with simple steatosis mice. Magnetic Resonance Imaging 2017; 38: 123 doi: 10.1016/j.mri.2016.12.027
|
43 |
Mingzhe Zheng, Ziwei Ai, Yuanyuan Guo, Yujiao Chen, Ping Xie, Wei An. Imbalance in ALR ubiquitination accelerates the progression of nonalcoholic steatohepatitis to hepatocellular carcinoma. Oncogene 2023; 42(4): 308 doi: 10.1038/s41388-022-02549-7
|